Clinical Trials Browser

Endometrial Neoplasms × Drug Therapy × Clear all

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06877572 2025-10-27

ECS Weight

Recruiting

50 enrolled

Gynecologic

Endometrial Neoplasms

NCT05857631 2025-04-15

PARCERII

Phase NA Recruiting

90 enrolled

Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT05364905 2023-09-06

ENDOVIE

Completed

200 enrolled

Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Endometrial Neoplasms

NCT05524389 2022-11-23

Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions

Phase 3 Not yet recruiting

624 enrolled

Gynecologic

Endometrial Neoplasms

NCT00739830 2015-07-01

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Phase 2 Completed

130 enrolled

Gynecologic

Endometrial Neoplasms

Clinical Trials

CHANCES

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

ECS Weight

PARCERII

RAINBO

ENDOVIE

Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)